Voyager Q2 net loss widens to $33.4M; cash runway extended into 2028

Voyager Therapeutics, Inc.

2025-Q2 EPS reported -$1.10 revenue$11,673,000

Net loss $33.4M in Q2 2025 vs $10.1M in Q2 2024; collaboration revenue fell to $5.2M from $29.6M.
Cash and marketable securities $262M; runway extended into 2028, enabling multiple clinical data readouts.
Added wholly-owned APOE program to Alzheimer's pipeline, fourth asset in franchise; tau PET data for VY7523 expected H2 2026.
Neurocrine-partnered FA and GBA1 gene therapy programs expected to enter clinical trials in 2026 after IND submissions in 2025.
Potential for $2.6B in development milestone payments from 11 partnered programs, including up to $35M from GBA and FA programs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.